Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

被引：8
|
作者：
Ravi, Praful [1 ]
Whelpley, Bridget [1 ]
Kelly, Emma [1 ]
Wolanski, Andrew [1 ,2 ]
Ritzer, Jolivette [1 ,2 ]
Robertson, Matthew [1 ,2 ]
Shah, Hina [1 ,2 ]
Morgans, Alicia K. [1 ]
Wei, Xiao X. [1 ]
Sunkara, Rajitha [1 ]
Pomerantz, Mark [1 ]
Taplin, Mary -Ellen [1 ]
Kilbridge, Kerry L. [1 ]
Choudhury, Atish D. [1 ]
Jacene, Heather [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 03期
关键词：
RESISTANT PROSTATE-CANCER; MULTICENTER; THERAPY;
D O I：
10.2967/jnumed.122.265194
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：349 / 350
页数：2
相关论文
共 50 条
  • [21] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [22] Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
    Wang, Jingnan
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Li, Fang
    Lin, Yansong
    Huo, Li
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 431 - 438
  • [23] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
    Mateo, Joaquin
    Zurita, Amado J.
    LANCET, 2024, 404 (10459): : 1174 - 1176
  • [24] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [25] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [26] Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes PostApproval
    Tuchayi, Abuzar Moradi
    Kim, Sarasa
    Morley, Amanda
    Saelee, Rachelle
    Wang, Yingbing
    Heath, Courtney Lawhn
    Juarez, Roxanna
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases
    Rashid, Narmeen S.
    Rami, Avina
    Lang, Min
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Jacene, Heather
    Ravi, Praful
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [28] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [29] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [30] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
12345